<DOC>
	<DOCNO>NCT01741688</DOCNO>
	<brief_summary>This observational study evaluate use efficacy intravenous ( IV ) tocilizumab routine clinical practice participant moderate severe rheumatoid arthritis . Eligible participant initiate tocilizumab treatment accordance local label follow 6 month .</brief_summary>
	<brief_title>An Observational Study Tocilizumab ( Actemra ) Participants With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adults , &gt; /= 18 year age Moderate severe rheumatoid arthritis accord revise ( 1987 ) American College Rheumatology ( ACR ) criteria Participants treat physician make decision commence tocilizumab treatment ( accordance local label ) ; include participant receive tocilizumab treatment within 8 week prior enrollment visit Participants receive tocilizumab 8 week prior enrollment visit Participants receive treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment tocilizumab History autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>